Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome
Copyright © 2022 Queiroz, Neves, Lima, Lopes, Torres, Vallinoto, Bichara, Santos, de Brito, da Silva, Leite, da Costa, Viana, Rodrigues, de Sarges, Cantanhede, da Silva, Bichara, Berg, Veríssimo, Carvalho, Henriques, Santos, Nunes, Costa, Viana, Carneiro, Palacios, Quaresma, Brasil-Costa, Santos, Falcão and Vallinoto..
The duration and severity of COVID-19 are related to age, comorbidities, and cytokine synthesis. This study evaluated the impact of these factors on patients with clinical presentations of COVID-19 in a Brazilian cohort. A total of 317 patients diagnosed with COVID-19 were included; cases were distributed according to clinical status as severe (n=91), moderate (n=56) and mild (n=170). Of these patients, 92 had acute COVID-19 at sample collection, 90 had already recovered from COVID-19 without sequelae, and 135 had sequelae (long COVID syndrome). In the acute COVID-19 group, patients with the severe form had higher IL-6 levels (p=0.0260). In the post-COVID-19 group, there was no significant difference in cytokine levels between groups with different clinical conditions. In the acute COVID-19 group, younger patients had higher levels of TNF-α, and patients without comorbidities had higher levels of TNF-α, IL-4 and IL-2 (p<0.05). In contrast, patients over age 60 with comorbidities had higher levels of IL-6. In the post-COVID-19 group, subjects with long COVID-19 had higher levels of IL-17 and IL-2 (p<0.05), and subjects without sequelae had higher levels of IL-10, IL-6 and IL- 4 (p<0.05). Our results suggest that advanced age, comorbidities and elevated serum IL-6 levels are associated with severe COVID-19 and are good markers to differentiate severe from mild cases. Furthermore, high serum levels of IL-17 and IL-2 and low levels of IL-4 and IL-10 appear to constitute a cytokine profile of long COVID-19, and these markers are potential targets for COVID-19 treatment and prevention strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in cellular and infection microbiology - 12(2022) vom: 10., Seite 922422 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.07.2022 Date Revised 07.12.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fcimb.2022.922422 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343669757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343669757 | ||
| 003 | DE-627 | ||
| 005 | 20231226021006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcimb.2022.922422 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343669757 | ||
| 035 | |a (NLM)35846757 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Queiroz, Maria Alice Freitas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Queiroz, Neves, Lima, Lopes, Torres, Vallinoto, Bichara, Santos, de Brito, da Silva, Leite, da Costa, Viana, Rodrigues, de Sarges, Cantanhede, da Silva, Bichara, Berg, Veríssimo, Carvalho, Henriques, Santos, Nunes, Costa, Viana, Carneiro, Palacios, Quaresma, Brasil-Costa, Santos, Falcão and Vallinoto. | ||
| 520 | |a The duration and severity of COVID-19 are related to age, comorbidities, and cytokine synthesis. This study evaluated the impact of these factors on patients with clinical presentations of COVID-19 in a Brazilian cohort. A total of 317 patients diagnosed with COVID-19 were included; cases were distributed according to clinical status as severe (n=91), moderate (n=56) and mild (n=170). Of these patients, 92 had acute COVID-19 at sample collection, 90 had already recovered from COVID-19 without sequelae, and 135 had sequelae (long COVID syndrome). In the acute COVID-19 group, patients with the severe form had higher IL-6 levels (p=0.0260). In the post-COVID-19 group, there was no significant difference in cytokine levels between groups with different clinical conditions. In the acute COVID-19 group, younger patients had higher levels of TNF-α, and patients without comorbidities had higher levels of TNF-α, IL-4 and IL-2 (p<0.05). In contrast, patients over age 60 with comorbidities had higher levels of IL-6. In the post-COVID-19 group, subjects with long COVID-19 had higher levels of IL-17 and IL-2 (p<0.05), and subjects without sequelae had higher levels of IL-10, IL-6 and IL- 4 (p<0.05). Our results suggest that advanced age, comorbidities and elevated serum IL-6 levels are associated with severe COVID-19 and are good markers to differentiate severe from mild cases. Furthermore, high serum levels of IL-17 and IL-2 and low levels of IL-4 and IL-10 appear to constitute a cytokine profile of long COVID-19, and these markers are potential targets for COVID-19 treatment and prevention strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a long COVID-19 | |
| 650 | 4 | |a risk factor | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-17 |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 700 | 1 | |a Neves, Pablo Fabiano Moura das |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Sandra Souza |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Jeferson da Costa |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Maria Karoliny da Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Vallinoto, Izaura Maria Vieira Cayres |e verfasserin |4 aut | |
| 700 | 1 | |a Bichara, Carlos David Araújo |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Erika Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a de Brito, Mioni Thieli Figueiredo Magalhães |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Andréa Luciana Soares |e verfasserin |4 aut | |
| 700 | 1 | |a Leite, Mauro de Meira |e verfasserin |4 aut | |
| 700 | 1 | |a da Costa, Flávia Póvoa |e verfasserin |4 aut | |
| 700 | 1 | |a Viana, Maria de Nazaré do Socorro de Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Fabíola Brasil Barbosa |e verfasserin |4 aut | |
| 700 | 1 | |a de Sarges, Kevin Matheus Lima |e verfasserin |4 aut | |
| 700 | 1 | |a Cantanhede, Marcos Henrique Damasceno |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Rosilene |e verfasserin |4 aut | |
| 700 | 1 | |a Bichara, Clea Nazaré Carneiro |e verfasserin |4 aut | |
| 700 | 1 | |a van den Berg, Ana Virgínia Soares |e verfasserin |4 aut | |
| 700 | 1 | |a Veríssimo, Adriana de Oliveira Lameira |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Mayara da Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Henriques, Daniele Freitas |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Carla Pinheiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Juliana Abreu Lima |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Iran Barros |e verfasserin |4 aut | |
| 700 | 1 | |a Viana, Giselle Maria Rachid |e verfasserin |4 aut | |
| 700 | 1 | |a Carneiro, Francisca Regina Oliveira |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios, Vera Regina da Cunha Menezes |e verfasserin |4 aut | |
| 700 | 1 | |a Quaresma, Juarez Antonio Simões |e verfasserin |4 aut | |
| 700 | 1 | |a Brasil-Costa, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Eduardo José Melo |e verfasserin |4 aut | |
| 700 | 1 | |a Falcão, Luiz Fábio Magno |e verfasserin |4 aut | |
| 700 | 1 | |a Vallinoto, Antonio Carlos Rosário |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cellular and infection microbiology |d 2011 |g 12(2022) vom: 10., Seite 922422 |w (DE-627)NLM220414289 |x 2235-2988 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:10 |g pages:922422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcimb.2022.922422 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 10 |h 922422 | ||